Daniel G Welch

age ~67

from Denver, CO

Get Report

Also known as:

Daniel Gerard Welch
Daniel D Welch
Dainel G Welch

Connected to:

Daniel Welch Phones & Addresses

Denver, CO
Avon, CO
San Francisco, CA
Darien, CT
Wilton, CT
Salem, NH

Work

Company:

Intermune inc
Address:

3280 Bayshore Blvd, Brisbane, CA 94005
Phones:

4154662200
Position:

Ceo
Industries:

Commercial Physical and Biological Research

Education

School / High School:

University of California, Hastings College of the Law

Ranks

Licence:

California - Active
Date:

2004

Name / Title

Company / Classification

Phones & Addresses

Daniel Welch
CEO

Intermune Inc
Commercial Physical and Biological Research

3280 Bayshore Blvd, Brisbane, CA 94005
Website: intermune.com

Daniel C Welch
Attorney

Wolkin & Curran Llp
Legal Services

555 Montgomery St, San Francisco, CA 94111

Daniel Welch
CEO

InterMune, Inc.
Pharmaceutical Preparations

3280 Bayshore Blvd, Brisbane, CA 94005

Daniel J. Welch
Manager, Treasurer

County of Champaign
General Government Executive Office · General Government · Public Finance/Taxation/Monetary Policy · Executive Office · Regulation/Administrative Transportation · Court · Urban/Community Development · Police Protection

2173283313, 2173843772, 2173843760, 2173843720

Daniel Welch
VP

BRIGHTWARE, INC

1331 N California Blvd STE 200, Walnut Creek, CA 94596

Daniel L. Welch
Incorporator

BIG VALLEY HOMES, INC

Daniel M. Welch

AMERICAN VETERANS OF WORLD II

Medicine Doctors

Daniel W. Welch

view source

Specialties:

Ophthalmology

Work:

Eye Specialists Of Mid-FloridaEye Specialists Of Mid Florida PA
407 Ave K SE, Winter Haven, FL 33880
8632943504 (phone), 8632948305 (fax)

Eye Specialists Of Mid-FloridaEye Specialists Mid Florida
5032 Us Hwy 27 N, Sebring, FL 33870
8633823900 (phone), 8633857442 (fax)

Eye Specialists Of Mid-FloridaEye Surgery & Laser Center
409 Ave K SE, Winter Haven, FL 33880
8632998574 (phone), 8632989034 (fax)

Education:

Medical School
University of Florida College of Medicine at Gainesville
Graduated: 1976

Procedures:

Lens and Cataract Procedures
Corneal Surgery
Eyeglass Fitting
Ophthalmological Exam

Conditions:

Acute Conjunctivitis
Cataract
Glaucoma
Keratitis
Diabetic Retinopathy

Languages:

English
Spanish

Description:

Dr. Welch graduated from the University of Florida College of Medicine at Gainesville in 1976. He works in Winter Haven, FL and 2 other locations and specializes in Ophthalmology. Dr. Welch is affiliated with Florida Hospital Heartland Medical Center and Winter Haven Hospital.

License Records

Daniel P Welch

License #:

30112 - Expired

Category:

Dual Towing Operator(IM)/VSF Employee

Expiration Date:

Feb 10, 2017

Daniel E Welch

License #:

281 - Expired

Expiration Date:

Jul 31, 1995

Type:

Journeyman Electrician

Lawyers & Attorneys

Daniel Carson Welch, San Francisco CA - Lawyer

view source

Address:

555 Montgomery St #1100, San Francisco, CA 94111
4159829390 (Office)

Licenses:

California - Active 2004

Education:

University of California, Hastings College of the Law
University of California - San Diego

Specialties:

Insurance - 34%
Tax - 33%
Constitutional - 33%

Daniel Welch - Lawyer

view source

ISLN:

913389230

Admitted:

1978

Daniel Welch - Lawyer

view source

Office:

Wolkin • Curran, LLP

Specialties:

Insurance
Tax
Constitutional
Construction
Surety Litigation

ISLN:

917729100

Admitted:

2004

University:

University of California, B.A., 2001

Law School:

University of California, Hastings College of the Law, J.D., 2004

Us Patents

Deuterated Forms Of Carbetocin And Analogs Thereof
view source
US Patent:

20210087233, Mar 25, 2021
Filed:

Nov 19, 2020
Appl. No.:

16/952251
Inventors:

Christopher Bryant - Burr Ridge IL, US
Joseph William Cormier - Bethesda MD, US
Daniel G. Welch - Denver CO, US
International Classification:

C07K 7/56
C07B 59/00
A61K 9/00
Abstract:

The present disclosure relates to deuterated forms of oxytocin, carbetocin and analogs thereof. The disclosed deuterated compounds may have similar biochemical potency and selectivity as the parent compound, and, in select instances, the selective deuteration may enable substantial benefits to their overall therapeutic profile, such as reduced adverse side effects with a decreased metabolic liability, extended pharmacological effective life, enhanced subject compliance, and/or may also decrease population pharmacokinetic variability. The present disclosure also includes pharmaceutical compositions of deuterated compounds, which may be used to treat various diseases and conditions.